Skin Cancer

Cutaneous squamous-cell carcinoma (CSCC) is a type of nonmelanoma skin cancer that affects the squamous cells in the middle and outer layers of the skin. CSCC occurs most frequently on sun-exposed areas, such as the scalp, ears, lips, face, neck, and backs of the hands. Less often, CSCC can be in the skin of the genital area. Read More ›

TON - August 2013 Vol 6 No 7 — September 4, 2013
Advanced melanoma has re-mained an intractable malignancy for decades, with dacarbazine the only approved therapy and high-dose interleukin-2 limited by significant toxicity. Read More ›

Vemurafenib is a relatively new effective option for the treatment of melanoma, but most patients who respond will develop resistance. Read More ›

TON - MARCH 2012 VOL 5, NO 2 — April 10, 2012

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), commonly referred to as non-melanoma skin cancers (NMSCs), are the most common types of cancers in the United States. These 2 cancers account for approximately 2 million cases of skin cancer annually.1 BCC is approximately 4 to 5 times more common than SCC.2 Although rarely metastatic, BCC and SCC can cause substantial local destruction involving extensive areas of soft tissue, cartilage, and bone, as well as disfigurement. Read More ›


TON - Daily — July 13, 2011

Continuous use of aspirin for 5 years or more reduces the risk of cutaneous melanoma by almost half, according to results of a case-control study. Continuous use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) also reduces risk, but only by 25%.

 

Read More ›

TON - Daily — June 3, 2011

Patients with stage IV or locally advanced stage III cutaneous melanoma experienced higher response rates and longer progression-free survival (PFS) when treated with a gp100 vaccine and interleukin-2 than with interleukin-2 alone, in a phase 3 randomized trial. Tumors in all 185 patients expressed HLA*A0201, which allowed presentation of the peptide vaccine to T cells. The researchers concluded that their results show the potential of immune agents in combination with other treatments in this patient population.

 

Read More ›

TON - August 2010, Vol 3, No 5 — September 14, 2010
Skin Cancer, edited by Paula Muehlbauer and Christine McGowan, is the first publication in the Oncology Nursing Society’s Site-Specific Cancer Series. Read More ›

TON - August 2010, Vol 3, No 5 — September 12, 2010

CHICAGO—A human monoclonal antibody that blocks a receptor that down regulates T-cell responses improves long-term survival in patients with previously treated advanced melanoma, according to the results of a phase 3 trial.

Read More ›

One in five Americans will develop skin cancer in his or her lifetime.1 More than 1 million cases of nonmelanoma skin cancer (NMSC) are estimated to go unreported each year. In 2009, more than 68,720 new cases of melanoma occurred, and melanoma caused 8650 deaths.1

Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: